SCHEMBL1999340

SCHEMBL1999340

O=[N+]([O-])c1cc(F)cc(F)c1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.57
ATM Q13315 1/20 0.57
ALDH1A1 P00352 2/20 0.45
HIF1A Q16665 2/20 0.45
TTR P02766 4/20 0.43
VCAM1 P19320 1/20 0.42
HSPB1 P04792 3/20 0.42
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
ESPL1 Q14674 1/20 0.38
PDE7A Q13946 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29966805 1.00 TDP1 (0.57) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL12066584 0.88 TDP1 (0.52) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL9811597 0.80 ALDH1A1 (0.59) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL4647699 0.80 TDP1 (0.55) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL57954 0.79 TDP1 (0.48) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL30616278 0.79 TDP1 (0.48) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL25355019 0.78 TTR (0.49) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL8091607 0.78 TDP1 (0.44) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL2078816 0.78 TTR (0.57) TDP1ATMALDH1A1HIF1ATTR
SCHEMBL17680657 0.78 TDP1 (0.44) TDP1ATMALDH1A1HIF1ATTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105646199-B The preparation technology of the trifluoro-benzoic acid of 3 chlorine 2,4,5 连云港威远精细化工有限公司 2017-10-03 CN claimed
WO-2015160562-A1 SULFONATION OF AROMATIC POLYMERS IN THE PRESENCE OF A POLYFLUORINATED BENZENE COMPOUND AS SWELLING AGENT ROHM AND HAAS COMPANY (US) 2015-10-22 WO claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
EP-4673141-A1 NBD1 MODULATORS AND METHODS OF USING THE SAME Sionna Therapeutics Inc. (US) 2026-01-07 EP disclosed
WO-2025031468-A1 HETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2025-02-13 WO disclosed
CN-118930547-A Ureido-substituted fused heteroaryl compounds, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2024-11-12 CN disclosed
CN-118684675-A Amide substituted pyrazoloheteroaryl compound, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-09-24 CN disclosed
EP-3928836-B1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-09-18 EP disclosed
WO-2024182751-A1 NBD1 MODULATORS AND METHODS OF USING THE SAME SIONNA THERAPEUTICS INC. (US) 2024-09-06 WO disclosed
CN-118515674-A Amide compound, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-08-20 CN disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 US disclosed
EP-2338935-A1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS COMPANY, LIMITED (JP) 2011-06-29 EP disclosed
US-7094900-B2 N-Aryl-2-oxazolidinones and their derivatives PHARMACIA & UPJOHN COMPANY LLC (US) 2006-08-22 US disclosed
EP-1539745-B1 N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES PHARMACIA & UPJOHN CO LLC (US) 2006-03-29 EP disclosed
EP-1539745-A1 N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES Pharmacia & Upjohn Company LLC (US) 2005-06-15 EP disclosed
US-20040072873-A1 N-Aryl-2-oxazolidinones and their derivatives GADWOOD ROBERT C (US) 2004-04-15 US disclosed
WO-2004014897-A1 N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-02-19 WO disclosed
EP-0596130-B1 PRODUCTION OF 2-HALO-3,5-DIFLUOROANILINE, INTERMEDIATE FOR PRODUCING THE SAME, AND PRODUCTION OF SAID INTERMEDIATE SDS BIOTECH CORP (JP) 1997-09-24 EP disclosed
EP-0596130-A1 PRODUCTION OF 2-HALO-3,5-DIFLUOROANILINE, INTERMEDIATE FOR PRODUCING THE SAME, AND PRODUCTION OF SAID INTERMEDIATE SDS Biotech K.K. (JP) 1994-05-11 EP disclosed
EP-0531958-A1 6-Aminoquinolones, their synthesis and their use as antibacterial agents MEDIOLANUM FARMACEUTICI S.P.A. (IT) 1993-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 TDP1 3691/4885ATM 3858/4885ALDH1A1 761/4885
US-20040072873-A1 N-Aryl-2-oxazolidinones and their derivatives OXA1L, NDUFS7, NDUFS6 TDP1 4591/4885ATM 3984/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.